CN119235837A - A composition specially used for resisting superficial fungal and bacterial infections and its preparation method - Google Patents
A composition specially used for resisting superficial fungal and bacterial infections and its preparation method Download PDFInfo
- Publication number
- CN119235837A CN119235837A CN202411752139.1A CN202411752139A CN119235837A CN 119235837 A CN119235837 A CN 119235837A CN 202411752139 A CN202411752139 A CN 202411752139A CN 119235837 A CN119235837 A CN 119235837A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- weight
- agent
- bacterial infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 208000035143 Bacterial infection Diseases 0.000 title claims abstract description 22
- 208000022362 bacterial infectious disease Diseases 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000002538 fungal effect Effects 0.000 title claims description 15
- 208000031888 Mycoses Diseases 0.000 title claims description 9
- 206010017533 Fungal infection Diseases 0.000 title claims description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 21
- 108010039918 Polylysine Proteins 0.000 claims abstract description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 20
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 14
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 14
- 229960000458 allantoin Drugs 0.000 claims abstract description 14
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 14
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- XNRNJIIJLOFJEK-UHFFFAOYSA-N sodium;1-oxidopyridine-2-thione Chemical compound [Na+].[O-]N1C=CC=CC1=S XNRNJIIJLOFJEK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 11
- 239000004202 carbamide Substances 0.000 claims abstract description 10
- OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 claims abstract description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 10
- 239000001632 sodium acetate Substances 0.000 claims abstract description 10
- 235000017454 sodium diacetate Nutrition 0.000 claims abstract description 10
- 229920004890 Triton X-100 Polymers 0.000 claims abstract description 8
- 239000013504 Triton X-100 Substances 0.000 claims abstract description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 7
- 229930015582 oxymatrine Natural products 0.000 claims abstract description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 7
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 claims abstract description 6
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 claims abstract description 6
- 229960005150 glycerol Drugs 0.000 claims abstract description 5
- 229940045136 urea Drugs 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000008399 tap water Substances 0.000 claims description 9
- 235000020679 tap water Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940051250 hexylene glycol Drugs 0.000 claims 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims 1
- 241000233866 Fungi Species 0.000 abstract description 13
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 12
- 239000007921 spray Substances 0.000 abstract description 12
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 abstract description 9
- 230000035699 permeability Effects 0.000 abstract description 5
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 229940088597 hormone Drugs 0.000 abstract description 3
- 239000005556 hormone Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 229920000832 Cutin Polymers 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract description 2
- 239000002085 irritant Substances 0.000 abstract 1
- 231100000021 irritant Toxicity 0.000 abstract 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 9
- 208000002894 beriberi Diseases 0.000 description 9
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 8
- 208000002474 Tinea Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 206010005913 Body tinea Diseases 0.000 description 5
- 201000010618 Tinea cruris Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 201000003875 tinea corporis Diseases 0.000 description 5
- 201000004647 tinea pedis Diseases 0.000 description 5
- 241001480036 Epidermophyton floccosum Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 241000223229 Trichophyton rubrum Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000012747 synergistic agent Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- -1 formaldehyde) Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000893976 Nannizzia gypsea Species 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 206010043866 Tinea capitis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000003539 bacterial infection method Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a composition specially resisting shallow fungus bacterial infection and a preparation method thereof. Mainly comprises an antibacterial agent, a synergist, a repairing agent and a solubilizer. The antibacterial agent comprises epsilon-polylysine hydrochloride, the synergist comprises oxymatrine, hexanediol, octaethylene glycol and sodium diacetate, the repairing agent comprises glycerol, urea, allantoin and dipotassium glycyrrhizinate, and the solubilizer comprises triton X-100, polyvinylpyrrolidone, sodium pyrrolidone carboxylate, sodium pyrithione and polyvinyl alcohol. The invention uses the antibacterial components from food grade and traditional Chinese medicine sources, has no hormone and irritant substances, has no corrosiveness, and is friendly to human body. Meanwhile, the composition is in a water-soluble and spray form, is convenient to use, can soften cutin and dead skin, has good permeability, continuously plays the role of killing fungi and bacteria, and achieves the purpose of treating the root cause.
Description
Technical Field
The invention relates to the field of antibacterial infection, in particular to a composition for superficial skin fungus bacterial infection and a preparation method thereof.
Background
Superficial fungal infections are the most common fungal infectious diseases, and include tinea pedis (beriberi), tinea cruris, tinea corporis, tinea capitis, onychomycosis (onychomycosis), and the like, according to the site of infection. Among them, beriberi is one of the most common dermatophyte infectious lesions, and symptoms are manifested by sweaty feet, foot odor, itching at affected parts, foaming, chapping, peeling and even pain. Due to the damp-heat environment of the foot, fungus bacteria are easy to quickly multiply at toe joints and skin folds, and meanwhile, due to the fact that microorganisms penetrate into the skin and the patient scratches themselves, beriberi is easy to repeatedly spread. Although skin infection such as beriberi is not a serious infectious disease, the infection brings serious inconvenience to the life of people and affects the mental health and the quality of life of people.
The pathogens of skin infection such as tinea cruris, tinea corporis and tinea pedis are mainly fungi, and one or more of trichophyton rubrum (trichophyton rubrum and trichophyton violaceum), trichophyton gypseum, epidermophyton floccosum and candida albicans are the most common. Bacterial infections such as staphylococcus aureus and streptococcus are also easily mixed. The fundamental method for treating beriberi consists in eliminating the growth and propagation environment of the microorganisms and administering antibacterial drugs for treating the root cause. Taking beriberi as an example, many antifungal creams for treating beriberi at present are only effective on fungi, have poor bacterial effect, are not easy to smear at the seams of toes and nails, and are mainly fat-soluble and poor in permeability. Many spray formulations contain acidic ingredients (salicylic acid, glacial acetic acid, benzoic acid, etc.), phenols (e.g., phenol), aldehydes (e.g., formaldehyde), hormones (e.g., dexamethasone), and are irritating or corrosive to the skin. Many of the traditional Chinese medicines and plant extracts for treating beriberi have complex formulas, unstable and definite components and are not beneficial to quality assurance.
Disclosure of Invention
The invention aims to solve the technical problem of providing a composition special for resisting shallow fungus bacterial infection, the main component is epsilon-polylysine hydrochloride, and the composition is a water-soluble nutritional biological preservative, and has the advantages of good permeability, high safety and good antibacterial effect.
In order to solve the technical problems, the invention adopts the following technical scheme:
The composition mainly comprises 1-3 parts by weight of antibacterial agent, 2-6 parts by weight of synergist, 5-10 parts by weight of repairing agent, 5-10 parts by weight of solubilizer and the balance of water.
Wherein the antibacterial agent is epsilon-polylysine hydrochloride (molecular weight 4130-5776). The synergistic agent is one or more than two of matrine oxide, hexanediol, octanediol and sodium diacetate. The repairing agent is one or more than two of glycerol, urea, allantoin and dipotassium glycyrrhizinate. The solubilizer is one or more than two of triton X-100, polyvinylpyrrolidone, sodium pyrrolidone carboxylate, sodium pyrithione and polyvinyl alcohol.
The invention also provides a preparation method of the composition, wherein the preparation process of the composition comprises the steps of A, weighing the antibacterial agent, the synergist and the repairing agent in parts by weight, adding tap water in about 500 parts by weight, stirring at normal temperature and normal pressure, and B, adding the solubilizer in parts by weight into the mixture in the step A, adding tap water in 1000 parts by weight, stirring at normal temperature and normal pressure, and dissolving.
The invention has the following beneficial effects:
1. The antibacterial main component epsilon-polylysine hydrochloride used in the invention is a water-soluble nutritional biological preservative, and has the characteristics of good permeability, high safety, good antibacterial effect, broad antibacterial spectrum, high temperature resistance, capability of being decomposed into nutrient substances lysine in intestines and stomach, and the like. The in vitro antimicrobial experiment shows that the antimicrobial component has good bactericidal effect on common trichophyton, epidermophyton floccosum, gypseum, candida and staphylococcus aureus in skin infection, and is an ideal substance for treating superficial fungus bacterial infection such as beriberi. Meanwhile, the invention uses the synergistic agent to assist sterilization so as to achieve the synergistic sterilization effect.
2. The repairing agent component used in the invention can soften the horny layer and dead skin of the skin of an affected part, so that the antibacterial component can quickly permeate into the deep part of the skin, thereby achieving good antibacterial effect. It also has antiinflammatory, wound repairing and skin regeneration promoting effects.
3. The composition specially used for resisting shallow fungus and bacterial infection and the preparation method thereof provided by the invention have the advantages of no hormone component, no corrosiveness, proper smell, good permeability and moisture retention, and convenience in use, and is favorable for patients to accept and use.
Detailed Description
The following examples are illustrative of the invention and are not intended to be limiting.
The composition mainly comprises 1-3 parts by weight of antibacterial agent, 2-6 parts by weight of synergist, 5-10 parts by weight of repairing agent, 5-10 parts by weight of solubilizer and the balance of water.
Wherein the antibacterial agent is epsilon-polylysine hydrochloride, has a molecular weight of 4130-5776, is a main antibacterial component, and has the effects of killing and inhibiting fungi and bacteria. The synergistic agent is one or more than two of matrine oxide, hexanediol, octanediol and sodium diacetate, and the synergistic agent is a novel and safe preservative, and plays a role in synergistic assistance in the invention. The repairing agent is one or more than two of glycerol, urea, allantoin and dipotassium glycyrrhizinate, and has effects of keeping moisture, softening dead skin cutin and preventing chapped skin, wherein the allantoin and dipotassium glycyrrhizinate have antiinflammatory effects, and can reduce skin redness, swelling and itching. Meanwhile, the collagen can be promoted to be synthesized by cells, and healing of skin ulcer is accelerated. The solubilizer is one or more than two of triton X-100, polyvinylpyrrolidone, pyrrolidone sodium carboxylate, sodium pyrithione and polyvinyl alcohol, and has the functions of increasing the compatibility of the components and improving the stability of the solution. All the components are commercial products.
The invention also provides a preparation method of the composition, wherein the preparation process of the composition comprises the steps of A, weighing the antibacterial agent, the synergist and the repairing agent in parts by weight, adding tap water in about 500 parts by weight, stirring at normal temperature and normal pressure, and B, adding the solubilizer in parts by weight into the mixture in the step A, adding tap water in 1000 parts by weight, stirring at normal temperature and normal pressure, and dissolving.
The present invention will be specifically described with reference to the following examples.
Examples
A composition for resisting superficial fungal bacterial infection comprises epsilon-polylysine hydrochloride, octaethylene glycol, glycerol, allantoin, triamcinolone X-100, and polyvinylpyrrolidone.
Spray 1 Kg of the composition was prepared, and the components were weighed as follows:
epsilon-polylysine hydrochloride 3.0 g;
Octanediol 5.0g;
Glycerol 5.0g;
allantoin 5.0g;
polyvinylpyrrolidone 5.0 g;
triton X-100.0 g;
Water was added to 1 Kg.
The preparation process of the spray of the composition comprises the following steps:
A. Uniformly stirring epsilon-polylysine hydrochloride, octanediol, glycerol, allantoin and polyvinylpyrrolidone with the weight as above, and then adding water to stir at normal temperature and normal pressure of about 0.5 Kg;
B. and C, adding the triton X-100 with the weight as above into the mixture in the step A, adding the triton X-100 to 1 Kg, fully stirring the mixture for half an hour at normal temperature and normal pressure, and standing the mixture to obtain a finished product.
Examples
A composition for resisting superficial mycotic bacterial infection is prepared from epsilon-polylysine hydrochloride, matrine oxide, hexanediol, urea, dipotassium glycyrrhizinate, sodium pyrithione and sodium pyrrolidone carboxylate.
The spray 1 Kg of the composition is prepared, and the components are weighed according to the following weight or volume:
epsilon-polylysine hydrochloride 2.5 g;
3.0g of oxymatrine;
Hexanediol 3.0 g;
urea 5.0 g;
Dipotassium glycyrrhizinate 2.0 g;
sodium pyrithione 3.0g;
Sodium pyrrolidone carboxylate 5.0 g;
Water was added to 1 Kg.
The preparation process of the spray of the composition comprises the following steps:
A. Uniformly stirring epsilon-polylysine hydrochloride, urea, dipotassium glycyrrhizinate, sodium pyrithione and sodium pyrrolidone carboxylate according to the weight, adding water to be about 0.5 Kg, and stirring at normal temperature and normal pressure;
B. And (C) adding the matrine oxide and the hexanediol with the weight as above into the mixture in the step (A), adding water to 1Kg, fully stirring for half an hour at normal temperature and normal pressure, and standing to obtain a finished product.
Examples
A composition for resisting superficial mycotic bacterial infection is prepared from epsilon-polylysine hydrochloride, matrine oxide, sodium diacetate, allantoin and polyvinyl alcohol.
1Kg of spray of the composition is prepared, and the components are weighed according to the following weight:
epsilon-polylysine hydrochloride 1.0 g;
oxymatrine 1.0 g;
sodium diacetate 1.0 g;
allantoin 5.0 g;
Polyvinyl alcohol 5.0 g;
tap water was added to 1Kg.
The preparation process of the spray of the composition comprises the following steps:
A. Uniformly stirring epsilon-polylysine hydrochloride, oxymatrine, sodium diacetate and allantoin according to the weight, adding water to the mixture and stirring the mixture at normal temperature and normal pressure of about 0.5 Kg;
B. and (C) adding the polyvinyl alcohol with the weight as above into the mixture in the step (A), adding water to fix the volume to 1 Kg, fully stirring for half an hour at normal temperature and normal pressure, and standing to obtain a finished product.
Examples
A composition for resisting superficial fungal bacterial infection comprises epsilon-polylysine hydrochloride, hexanediol, octanediol, allantoin, dipotassium glycyrrhizinate, polyvinylpyrrolidone and sodium pyrithione.
Spray 1 Kg of the composition was prepared, and the components were weighed as follows:
epsilon-polylysine hydrochloride 1.5 g;
Hexanediol 4.0 g;
octanediol 2.0g;
Allantoin 3.0g;
Dipotassium glycyrrhizinate 2.0 g;
polyvinylpyrrolidone 5.0 g;
Sodium pyrithione 5.0 g;
Tap water was added to 1 Kg.
The preparation process of the spray of the composition comprises the following steps:
A. Uniformly stirring epsilon-polylysine hydrochloride, hexanediol, octanediol, allantoin and dipotassium glycyrrhizinate according to the weight, adding water to about 0.5 Kg, and stirring at normal temperature and normal pressure;
B. And C, adding polyvinylpyrrolidone and sodium pyrithione with the weight as above into the mixture in the step A, adding water to fix the volume to 1 Kg, fully stirring for half an hour at normal temperature and normal pressure, and standing to obtain a finished product.
Examples
A composition for preventing and treating bacterial infection of superficial fungi is prepared from epsilon-polylysine hydrochloride, matrine oxide, octaethylene glycol, sodium diacetate, urea,
Dipotassium glycyrrhizinate, triton X-100 and sodium pyrithione.
Spray 1 Kg of the composition was prepared, and the components were weighed as follows:
epsilon-polylysine hydrochloride 1.0 g;
Oxymatrine 2.0 g;
2.0 parts of octanediol;
Sodium diacetate 2.0 g;
urea 3.0g;
dipotassium glycyrrhizinate 5.0 g;
Triton X-100.0 Kg;
Sodium pyrithione 5.0 g;
Tap water was added to 1 Kg.
The preparation process of the spray of the composition comprises the following steps:
A. uniformly stirring epsilon-polylysine hydrochloride, oxymatrine, octaethylene glycol, sodium diacetate, urea and dipotassium glycyrrhizinate according to the weight, and then adding water to stir at normal temperature and normal pressure of about 0.5 Kg;
B. And C, adding the triton X-100 and the sodium pyrithione with the weights as above into the mixture in the step A, adding water to fix the volume to 1Kg, fully stirring for half an hour at normal temperature and normal pressure, and standing to obtain a finished product.
To verify the effect of the examples of the present invention, the antibacterial effect of the compositions for combating superficial fungal bacterial infections according to examples 1, 2, 3,4, 5 on common microorganisms in tinea cruris, tinea corporis, tinea pedis and tinea capitis was examined, and the results obtained in Table 1 were that the ①-⑤ composition prepared according to the above examples had good inhibitory or bactericidal effects on Trichophyton rubrum, epidermophyton floccosum, epidermophyton candidum and Staphylococcus aureus.
| Microorganism species | ① | ② | ③ | ④ | ⑤ |
| Trichophyton rubrum (Fr.) karst | 42 | 50 | 49 | 48 | 59 |
| Epidermophyton floccosum | 42 | 40 | 39 | 40 | 46 |
| Trichophyton gypseum (L.) Makino | 31 | 33 | 30 | 31 | 34 |
| Candida albicans | 42 | 42 | 41 | 42 | 36 |
| Staphylococcus aureus | 24 | 25 | 24 | 26 | 22 |
The concentration of the composition is 5 times of the dilution of the stock solution
The diameter of the inhibition ring (average value of three measured values) is in mm, and the diameter of the control group without mildew inhibitor is 6mm (namely the diameter of the blank paper sheet per se)
2. Using observation
2.1 All observed subjects before treatment were subjected to clinical direct microscopic examination, positive diagnosis was made as tinea, and then treatment was performed by applying the composition No. 4 of the fourth example, which is specially used for the treatment against superficial fungal bacterial infection, to the affected area 2-3 times daily, and clinical observation was performed every two weeks and direct microscopic examination was performed 1 time. Of 106 cases with complete data, 32 men and 74 women, 23 cases with tinea cruris, 27 cases with tinea corporis and 56 cases with tinea pedis, wherein the same patient has 1-3 cases.
2.2 Standard of efficacy
Healing-skin lesion regressing, negative topical fungal doctor blade microscopy
Improvement-improvement of skin lesions, disappearance of lesions, alleviation of subjective symptoms, but microscopic examination of a small number of hyphae by fungal doctor blade was still positive.
The invalid-subjective symptoms and skin lesions were not ameliorated, and the fungal doctor blade microscopy was still positive.
2.3 Therapeutic results
89 Cases were cured, 84%, 11 cases were improved, 10.4%, 6 cases were not effective, and 5.6%. The total effective rate is 94.4%. The best improvement time of clinical manifestations is 3 days, the cure time is generally 7-10 days, and the slowest time is 45 days. In some cases of failure and improvement, 2 cases of failure have local allergic reactions, which cause erythema and are disabled, due to excessive lesion area and lack of adherence to medication.
The use observation shows that the composition No. 4 is specially used for resisting superficial fungal bacterial infection, has definite curative effect on skin tinea caused by fungi, such as tinea cruris, tinea corporis and tinea pedis, has simple preparation, convenient use and small skin irritation, and is worthy of popularization.
The described embodiments of the present invention are intended to be illustrative only and not to limit the scope of the invention, and various other alternatives, modifications, and improvements may be made by those skilled in the art within the scope of the invention, and therefore the invention is not limited to the above embodiments but only by the claims.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411752139.1A CN119235837B (en) | 2024-12-02 | 2024-12-02 | A composition specially used for resisting superficial fungal and bacterial infections and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411752139.1A CN119235837B (en) | 2024-12-02 | 2024-12-02 | A composition specially used for resisting superficial fungal and bacterial infections and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN119235837A true CN119235837A (en) | 2025-01-03 |
| CN119235837B CN119235837B (en) | 2025-03-25 |
Family
ID=94032122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411752139.1A Active CN119235837B (en) | 2024-12-02 | 2024-12-02 | A composition specially used for resisting superficial fungal and bacterial infections and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119235837B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031583A (en) * | 2004-08-18 | 2007-09-05 | 诺瓦生命科学有限公司 | Antimicrobial peptides containing arginine and/or lysine motif |
| US20090092576A1 (en) * | 2007-10-09 | 2009-04-09 | Humco Holding Group, Inc. | Antifungal treatment of nails |
| CN101822736A (en) * | 2010-03-08 | 2010-09-08 | 深圳市倍安蒂科技有限公司 | Novel biological bactericide and preparation method thereof |
| CN103687601A (en) * | 2011-05-16 | 2014-03-26 | 星法马私人有限公司 | Methods of treating or preventing bacterial vaginosis |
| CN106176286A (en) * | 2016-08-30 | 2016-12-07 | 华熙福瑞达生物医药有限公司 | Hyaluronic acid skin nursing film and preparation method and application |
| WO2022035031A1 (en) * | 2020-08-14 | 2022-02-17 | 비엘엔에이치 주식회사 | Pharmaceutical composition for prevention or treatment of tinea |
-
2024
- 2024-12-02 CN CN202411752139.1A patent/CN119235837B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101031583A (en) * | 2004-08-18 | 2007-09-05 | 诺瓦生命科学有限公司 | Antimicrobial peptides containing arginine and/or lysine motif |
| US20090092576A1 (en) * | 2007-10-09 | 2009-04-09 | Humco Holding Group, Inc. | Antifungal treatment of nails |
| CN101822736A (en) * | 2010-03-08 | 2010-09-08 | 深圳市倍安蒂科技有限公司 | Novel biological bactericide and preparation method thereof |
| CN103687601A (en) * | 2011-05-16 | 2014-03-26 | 星法马私人有限公司 | Methods of treating or preventing bacterial vaginosis |
| CN106176286A (en) * | 2016-08-30 | 2016-12-07 | 华熙福瑞达生物医药有限公司 | Hyaluronic acid skin nursing film and preparation method and application |
| WO2022035031A1 (en) * | 2020-08-14 | 2022-02-17 | 비엘엔에이치 주식회사 | Pharmaceutical composition for prevention or treatment of tinea |
Non-Patent Citations (3)
| Title |
|---|
| RAVI PILLAI ET AL.: "化妆品配方中少用或不用防腐剂的选择", 《第九届中国化妆品学术研讨会论文集（上）》, 31 December 2012 (2012-12-31), pages 257 - 263 * |
| SUZUKI, TOMOHIRO ET AL: "A Case of Tinea Faciei, Tinea Corporis, and Tinea Unguium with Dermatophytoma Successfully Treated with Oral Fosravuconazole L-lysine Ethanolate", 《 MEDICAL MYCOLOGY JOURNAL》, 2 March 2021 (2021-03-02), pages 1 - 4 * |
| 郑柏根: "ε-聚赖氨酸盐在方便湿面中的应用及其增效途径研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》, no. 4, 15 April 2022 (2022-04-15), pages 024 - 202 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119235837B (en) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA018425B1 (en) | Pharmaceutical, disinfectant or preservation extract of trigonella foenum-graecum, method for preparing and use thereof | |
| WO2017101790A1 (en) | Pharmaceutical composition for treating cutaneous pruritus and use thereof | |
| CN106806368A (en) | A kind of antimycotic medicine for external application composition | |
| CN117815181A (en) | Hoof and mouth spray for cattle and sheep with foot rot and preparation method and application thereof | |
| CN101843637B (en) | External spray for preventing and treating beriberi and preparation method | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| CN119235837B (en) | A composition specially used for resisting superficial fungal and bacterial infections and its preparation method | |
| CN107496792B (en) | Gel for treating onychomycosis by diminishing inflammation and resisting bacteria and preparation method thereof | |
| WO2012035478A2 (en) | Antifungal varnish composition | |
| US20110118220A1 (en) | Composition of bifonazole and its use | |
| CN117018053A (en) | Foot antibacterial spray and preparation method and application thereof | |
| CN110974861A (en) | Blumea balsamifera oil liposome | |
| CN111166841B (en) | Skin disinfection combined medicament and preparation method and use method thereof | |
| US11318182B1 (en) | Plant extract for skin infections | |
| CN108671059A (en) | A kind of liquid and preparation method thereof for treating onychomycosis | |
| CN104523711B (en) | Ketone Kang Tasuo emulsifiable pastes and preparation method thereof | |
| CN115590934A (en) | A kind of gynecological lotion and its preparation method and application | |
| CN107412647B (en) | External preparation for sterilizing, relieving itching and retaining fragrance | |
| CN102973680B (en) | External linimentum for treating superficial fungal infection and preparation method of external linimentum | |
| CN111358851A (en) | Gel for treating pet skin diseases and preparation method thereof | |
| CN111388529A (en) | Pharmaceutical composition for treating onychomycosis and preparation method thereof | |
| CN111012740A (en) | Enconazole liquid preparation for external use and preparation method thereof | |
| CN105434431B (en) | A kind of multi-functional externally used antimicrobial preparation and its preparation method and application | |
| CN1047521C (en) | Medicinal preparation for preventing and treating skin diseases | |
| CN113995826A (en) | External use infusion for treating onychomycosis by traditional Chinese medicine combination and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |